104 results
Page 3 of 6
D/A
n5k7zwq32 yxywqp
30 Sep 13
$4.95M in equity / options / securities to be acquired, sold $2.18M, 51 investors
12:00am
D
74mc8nnnn006dw6xl
19 Feb 21
$10.24M in equity / options, sold $10.24M, 18 investors
9:26am
DEF 14A
zps68 xbiksxtx
26 Apr 19
Definitive proxy
5:02pm
8-K
bglwpj xxx4sgr
14 Jul 22
Departure of Directors or Certain Officers
3:51pm
8-K
EX-99.1
h2l8 6f6g
10 Jul 13
Regulation FD Disclosure
12:00am
8-K
EX-99.1
91ya30i o4dtd
26 Sep 14
Regulation FD Disclosure
12:00am
8-K
EX-10.1
mb7hr86qtp
27 Aug 20
Entry into a Material Definitive Agreement
9:30am
8-K
EX-10.1
7mhfg
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am
8-K
ppc9 tfbjhuo956e51
12 Oct 17
Entry into a Material Definitive Agreement
12:00am
8-K
EX-99.1
37dccabxlx
3 Nov 14
Separation and Severance Agreement
12:00am
8-K
EX-10.1
lpth 1h69moqfdk
20 Aug 20
Entry into a Material Definitive Agreement
9:30am
8-K
EX-10.1
tq7a cm2akn
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
8-K
EX-10.1
58j1ex0cq
30 Jan 24
Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
10:46am
DEF 14C
vjq15ge186o8pitm3diw
18 Jul 19
Information statement
2:34pm
DEF 14C
onyoar7
27 May 20
Information statement
5:15pm
PRE 14C
tu12a7 yes
2 Jul 19
Preliminary information
5:18pm
PRE 14C
v67bw9oq6g7av c3
15 May 20
Preliminary information
1:50pm